AccScience Publishing / EJMO / Volume 1 / Issue 1 / DOI: 10.14744/ejmo.2017.29392
CASE REPORT

A Rare Cause of Acute Kidney Injury: Renal Arterial Thrombosis in a Small Cell Lung Cancer Patient

Osman Kostek1 Muhammet Bekir Hacioglu1 Seval Orman2 Ceren Cetin2 Nil Su Kodal2 Bulent Erdogan1 Sernaz Uzunoglu1 Irfan CiCin1
Show Less
1 Deparment of Medical Oncology, Trakya University Faculty of Medicine, Edirne, Turkey
2 Deparment of Internal Medicine, Trakya University Faculty of Medicine, Edirne, Turkey
Submitted: 19 May 2017 | Accepted: 21 July 2017 | Published: 3 August 2017
© 2017 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Renal artery thromboembolism is a rare cause of acute kidney injury. Hypercoagulable state is an important reason renal arterial thrombosis may occur. Cancer cells activate coagulation systems via various pathways, leading to the development of a prothrombogenic state. Presently described is the very rare condition of renal artery thromboembolism in a patient with extensive-stage small cell lung cancer.

Keywords
Acute kidney injury
renal arterial thrombosis
small cell lung cancer
Conflict of interest
None declared.
References

1.Falanga A, Russo L, Milesi V. The coagulopathy of cancer. Curr Opin Hematol 2014;21:423–9. [CrossRef]

2. Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011;22 Suppl 6:vi85–92. [CrossRef]

3. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36–46. [CrossRef]

4. Qureshi A, Mitchell C, Richards S, Vora A, Goulden N. Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe. Br J Haematol 2010;149:410–3. [CrossRef]

5. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003;107:I17–21. [CrossRef]

6. Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol 1998;160:2021–4. [CrossRef]

7. Barni S, Labianca R, Agnelli G, Bonizzoni E, Verso M, Mandalà M, et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med 2011;9:179. [CrossRef]

8. Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, et al. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol 2012;30:4416–26. [CrossRef]

9. Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846–50. [CrossRef]

10. Bolderman R, Oyen R, Verrijcken A, Knockaert D, Vanderschueren S. Idiopathic renal infarction. Am J Med 2006;119:356. e9–12. [CrossRef]

11. Korzets Z, Plotkin E, Bernheim J, Zissin R. The clinical spectrum of acute renal infarction. Isr Med Assoc J 2002;4:781–4.

12. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ, et al. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA 1981;245:831–5. [CrossRef]

Share
Back to top
Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing